64 results
8-K
EX-10.2
PLX
Protalix BioTherapeutics Inc.
26 Aug 21
Protalix BioTherapeutics Announces Closing of Private Note Exchange
7:16am
8-K
EX-10.1
PLX
Protalix BioTherapeutics Inc.
26 Aug 21
Protalix BioTherapeutics Announces Closing of Private Note Exchange
7:16am
8-K
EX-10.1
esx 0y00wlgjanj
13 Aug 21
Protalix BioTherapeutics Announces Private Note Exchange
7:05am
8-K
EX-10.2
0sb5w
8 Jun 20
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
5:04pm
8-K
EX-10.1
hj6irrpi3ft3dathhj
8 Jun 20
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
5:04pm
8-K
EX-10.1
yuubt dv1n
12 Mar 20
Protalix BioTherapeutics Announces $43.7 Million in Financing to
8:04am
8-K
EX-10.1
v0nu0m2182
29 Jul 19
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
7:09am
8-K
EX-10.1
t7yu423p
21 May 19
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
7:35am
8-K
EX-10.1
fj3r vbbq24bu
25 Jul 17
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
12:00am
8-K
EX-10.2
ubn0 w6v1g6n1twock4
25 Jul 17
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
12:00am
8-K
EX-10.4
5yk3 9xcojdio0y3s1
7 Dec 16
Entry into a Material Definitive Agreement
12:00am